Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af sikkerhed og effektivitet af iNstroke 4F tromboaspirationskateteret hos patienter med akut iskæmisk apopleksi forårsaget af primære distale medium vessel okklusioner (DMVO) (4-NiVO)

3. november 2026 opdateret af: iVascular S.L.U.

Prospektiv, enarms, multicentrisk undersøgelse til evaluering af effektiviteten og sikkerheden af iNstroke 4F tromboaspirationskateteret hos patienter med akut iskæmisk apopleksi på grund af primære distale mellemstore karokklusioner (DMVO).

Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study is an exploratory, interventional, open label, single-arm, multi-centre prospective clinical investigation.

In this post-market clinical investigation, the aim is to further evaluate the efficacy and safety of the iNstroke 4F aspiration catheter, with a view to, in future clinical investigations, comparing the product with the standard therapy or with other similar products. In addition, this clinical investigation will generate results that could be used to further assess the safety and effectiveness of mechanical thrombectomy for the treatment of DMVO.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

57

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Barcelona, Spanien
        • Hospital Universitario Vall d'Hebron
      • Madrid, Spanien
        • Hospital Universitario 12 de Octubre
      • Madrid, Spanien
        • Hospital Universitario La Paz
      • Madrid, Spanien
        • Hospital Universitario de Getafe
      • Murcia, Spanien
        • Hospital Clínico Universitario Virgen de Arrixaca
      • Bonn, Tyskland
        • Universitätsklinikum Bonn
      • Kiel, Tyskland
        • Universitätsklinikum Schleswig-Holstein
      • Marburg, Tyskland
        • Klinikum Marburg
      • Nuremberg, Tyskland
        • Klinikum Nürnberg
      • Recklinghausen, Tyskland
        • Knappschaftskrankenhaus Recklinghausen
      • Budapest, Ungarn
        • Semmelweis University Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Subjects aged ≥ 18 years.
  • Subjects with symptom onset up to 24 hours.
  • Isolated primary demonstrated occlusion in a distal medium vessel (Non-dominant or distal M2-MCA segment, M3 or M4 segments of MCA, A2-A3 segments of ACA, P1, P2 and P3 segments of PCA) identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
  • Baseline NIHSS score ≥5 assessed before the procedure.
  • Pre-stroke mRS score ≤ 2.
  • Subjects with an ASPECTS score ≥ 6.
  • Informed consent obtained in accordance with the applicable country-specific regulations and as approved by the Ethics Committee (EC).

Exclusion Criteria:

  • Subjects aged < 18.
  • Suspected secondary DMVO. Suspicion or evidence of primary LVO whether it has been treated or not with fibrinolytic therapy or mechanical thrombectomy that subsequently develops a DMVO.
  • Baseline NIHSS score <5 assessed before the procedure.
  • Pre-stroke mRS score >2.
  • Subjects with an ASPECTS score <6.
  • Severe comorbidity and/or shortened life expectancy that will likely prevent improvement or follow up or that will render the procedure unlikely to benefit the patient.
  • Severe allergy to contrast media.
  • Subjects with intracranial atherosclerotic occlusive disease or extra- or intracranial dissection.
  • Medical history of thrombocytopenia (Platelets <100,000).
  • Subjects with tandem occlusions (evidence of complete occlusion, high-grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery).
  • Subjects with occlusions in multiple vessels (e.g., MCA-M3 and ACA-A2), whether or not they undergo mechanical thrombectomy.
  • Subjects with cancer (with or without metastases) who have a life expectancy of less than 6 months.
  • Subjects participating in a clinical trial at the moment of the inclusion.
  • Subjects with pre-existing neurological or psychiatric illness that could confound the neurological or functional assessments.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Thromboaspiration using iNstroke 4F aspiration catheter

No comparator will be used in this clinical investigation as it is an exploratory study of a CE-marked medical device to be used within the scope of its intended purpose.

Patients to undergo thromboaspiration with iNstroke 4F

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Recanalization Endpoint
Tidsramme: Intra-procedure

Recanalization rate with a modified thrombolysis in cerebral infarction scale (mTICI) score ≥2b in ≤3 revascularization passes using iNstroke 4F aspiration catheter, alone or in conjunction with a SR.

Intra-procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Recanalization Endpoint
Tidsramme: Intra-procedure

Proportion of subjects treated with iNstroke 4F alone with complete recanalization in primary DMVO defined as an mTICI ≥2b, after iNstroke 4F aspiration catheter alone (ADAPT) was used as a first-line therapy

Intra-procedure
Recanalization Endpoint
Tidsramme: Intra-procedure

Proportion of subjects treated with iNstroke 4F in conjunction with a stent retriever having complete recanalization in primary DMVO defined as achieving an mTICI ≥2b, after iNstroke 4F aspiration catheter, in conjunction with a stent retriever (SR), was used as a first-line therapy.

Intra-procedure
Recanalization Endpoint
Tidsramme: Intra-procedure

Proportion of subjects with mTICI≥2b, mTICI≥2c and mTICI 3 after first pass with iNstroke 4F aspiration catheter used both alone and in conjunction with a SR.

Intra-procedure
Recanalization Endpoint
Tidsramme: Intra-procedure

Time from groin puncture to achievement of complete recanalization (mTICI ≥2b), or if not achieved, until the final angiogram time, in patients treated with iNstroke 4F aspiration catheter, alone or in conjunction with a SR, as a first-line therapy.

Intra-procedure
Recanalization Endpoint
Tidsramme: Intra-procedure

Proportion of subjects in which direct contact with thrombus is achieved with iNstroke 4F aspiration catheter.

Intra-procedure
Clinical Endpoint
Tidsramme: 90 day

Proportion of subjects achieving a modified Rankin scale (mRS) score of 0-2 at the 90-day (±14 days) post-procedure follow-up visit.

90 day
Safety Endpoint
Tidsramme: 24 (-8/+12) hours

Occurrence of SICH (according to SITS-MOST (13) and ECASS criteria (14)) within 24 (-8/+12) hours post-procedure, assessed by magnetic resonance imaging (MRI)/computed tomography (CT).

Intracerebral Haemorrhage (ICH) is defined as the presence of extravascular blood in the brain or within the skull (local or remote parenchymal hematoma type 2, subarachnoid haemorrhage, and/or intraventricular haemorrhage) detected on the post-procedure imaging scan. ICH is considered symptomatic (SICH) if it is associated with a clinical deterioration, determined by a worsening/increase on the National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points, or if it causes death and is identified as the predominant cause of neurological deterioration.

24 (-8/+12) hours
Safety Endpoint
Tidsramme: Intra-procedure

Occurrence of embolization in a previously non-involved (or new) territory as seen on the final control angiogram at the end of the procedure.

Intra-procedure
Safety Endpoint
Tidsramme: Intra-procedure

Occurrence of embolization in distal medium territory to the proximal occlusion as seen on the final control angiogram at the end of the procedure.

Intra-procedure
Safety Endpoint
Tidsramme: During hospital admission

Inhospital mortality rate related to the procedure during hospital admission.

During hospital admission
Safety Endpoint
Tidsramme: 90 days (±14 days) after the procedure.

Occurrence of devices and procedure related adverse events within 90 days (±14 days) after the procedure.

90 days (±14 days) after the procedure.
Safety Endpoint
Tidsramme: Intra-procedure

Occurrence of procedure-related complications: arterial perforation, arterial dissection and severe vasospasm in the target vessel.

Intra-procedure

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Exploratory Recanalization Endpoint
Tidsramme: Intra-procedure

Proportion of subjects in which a switch of technique (from ADAPT to combined or from combined to ADAPT) with iNstroke 4F aspiration catheter was used to successfully perform the thrombectomy.

Intra-procedure
Exploratory Recanalization Endpoint
Tidsramme: Intra-procedure

Proportion of subjects in which an aspiration catheter device with a 4F caliber different from iNstroke 4F aspiration catheter was used as a rescue therapy.

Intra-procedure
Exploratory Recanalization Endpoint
Tidsramme: Intra-procedure

Proportion of cases in which iNstroke 4F aspiration catheter (alone or in conjunction with a SR) successfully reached the site of occlusion.

Intra-procedure
Exploratory Recanalization Endpoint
Tidsramme: Intra-procedure

Number of passes with iNstroke 4F aspiration catheter until recanalization.

Intra-procedure
Exploratory Recanalization Endpoint
Tidsramme: Intra-procedure

Visibility of the catheter during the thrombectomy rated from 0 to 5 (being 0 the worst and 5 the best score).

Intra-procedure
Exploratory Clinical Endpoint
Tidsramme: 24 (-8/+12) hours post-procedure.

Proportion of subjects with rapid neurological improvement, defined as a decrease of more than 4 points on the NIHSS scale, during the first 24 (-8/+12) hours post-procedure.

24 (-8/+12) hours post-procedure.
Exploratory Clinical Endpoint
Tidsramme: First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.

Proportion of subjects with a reduction of ≥8 points on the NIHSS scale during the first 24 (-8/+12) hours post-procedure, or with a NIHSS score of 0-1 at 3 days (±24 hours) or at the time of discharge, whichever occurs first.

First 24 (-8/+12) hours post-procedure or 3 days (±24 hours) or at the time of discharge, whichever occurs first.
Exploratory Clinical Endpoint
Tidsramme: 24 (-8/+12) hours.

Median of NIHSS score at 24 (-8/+12) hours.

24 (-8/+12) hours.
Exploratory Clinical Endpoint
Tidsramme: 3 days (±24 hours) post procedure

Median of NIHSS score at 3 days (±24 hours) or at the time of patient discharge, whichever occurs first.

3 days (±24 hours) post procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. november 2025

Primær færdiggørelse (Anslået)

1. november 2026

Studieafslutning (Anslået)

1. november 2026

Datoer for studieregistrering

Først indsendt

9. december 2025

Først indsendt, der opfyldte QC-kriterier

12. januar 2026

Først opslået (Faktiske)

22. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 4-NiVO-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .